Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Frank O'Donnell
CEO | Chief Executive Officer | 74 | 13.12.22 |
James McNulty
DFI | Director of Finance/CFO | 73 | 13.12.22 |
Amy M. McCord
LAW | General Counsel | - | 01.01.19 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Frank O'Donnell
CEO | Chief Executive Officer | 74 | 13.12.22 |
Samuel Sears
BRD | Director/Board Member | 80 | 02.08.13 |
Ronald Osman
BRD | Director/Board Member | 78 | 23.08.23 |
Niraj Vasisht
BRD | Director/Board Member | 61 | 13.12.22 |
Michelle Yanez
BRD | Director/Board Member | 52 | 13.12.22 |
Michael Jerman
BRD | Director/Board Member | 40 | 24.05.23 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 172 323 545 | 71 550 692 ( 41,52 %) | 0 | 41,52 % |
Unternehmenskontakt
Inhibitor Therapeutics, Inc.
449 South 12th Street Unit 1705
33602, Tampa
+813 864 2562
http://www.inhibitortx.com![Straße HedgePath Pharmaceuticals Inc](https://cdn.zonebourse.com/static/address/13988991.png)
Sektor
% 1. Jan. | Kap. | |
---|---|---|
+25,83 % | 46,56 Mrd. | |
+45,38 % | 41,67 Mrd. | |
+0,69 % | 41,16 Mrd. | |
+30,52 % | 32,4 Mrd. | |
+22,30 % | 28,18 Mrd. | |
-6,35 % | 28,1 Mrd. | |
+49,25 % | 14,52 Mrd. | |
+49,18 % | 13,74 Mrd. | |
+3,45 % | 12,17 Mrd. |